Read this company snapshot
Daily valuation snapshot
Kalaris Therapeutics, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $2.36
- Market capitalization (USD)
- $56,179,755.16
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.97
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research KLRS in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research KLRS in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing KLRS with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $2.36 |
| Market capitalization (USD) | $56,179,755.16 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.97 |
No matching rows. Clear the filter to see all records.
Read KLRS's valuation metrics
Company size
Kalaris Therapeutics, Inc. Common Stock's recorded market capitalization is $56,179,755.16. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
KLRS's recorded price-to-book ratio is 0.97. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Kalaris Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about KLRS. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow KLRS's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.